Match
|
Document |
Document Title |
|
US20070218138 |
Pharmaceutical Compositions
Forms and formulations of VX-950 and uses thereof. |
|
US20170100356 |
NOVEL FORMULATION OF DICLOFENAC
The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in... |
|
US20120328700 |
METHODS AND COMPOSITIONS FOR REGENERATING CONNECTIVE TISSUE
Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive... |
|
US20120141583 |
ALCOHOL RESISTANT DOSAGE FORMS
Opioid controlled release formulation resistant to alcohol extraction of the opioid. |
|
US20110171310 |
HYDROGEL COMPOSITIONS COMPRISING VASOCONSTRICTING AND ANTI-HEMORRHAGIC AGENTS FOR DERMATOLOGICAL USE
The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. |
|
US20100272796 |
SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into... |
|
US20100255068 |
HAIR-LIKE SHAPED HYDROGELS FOR SOFT TISSUE AUGMENTATION
Hair-like shaped crosslinked hydrogels and methods for preparing such crosslinked hydrogels and are provided. |
|
US20100151013 |
Gastric acid secretion inhibiting composition
An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on... |
|
US20090123547 |
Methods and Compositions for Regenerating Connective Tissue
Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive... |
|
US20090117191 |
Controlled release tramadol formulations
A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient. |
|
US20080181952 |
Perfusive Organ Hemostasis
Disclosed are compositions, methods and kits to control bleeding through the use of an internal occluder based on polymeric solutions, including use of reverse thermosensitive polymers in... |
|
US20070110677 |
DELIVERY OF DRUGS TO MUCOSAL SURFACES
Liquid pharmaceutical compositions for administration to a mucosal surface, including fentanyl and a pectin with a low degree of esterification are described. Such compositions gel, or can be... |
|
US20070104656 |
Matrices Formed of Polymer and Hydrophobic Compounds For Use in Drug Delivery
A lipid or other hydrophobic or amphiphilic compound (collectively referred to herein as “hydrophobic compounds”) is integrated into a polymeric matrix for drug delivery to alter drug release... |
|
US20070065483 |
In vivo formed matrices including natural biodegradable polysaccharides and uses thereof
In vivo formed matrices including natural biodegradable polysaccharides are described. The matrix is formed from a plurality of natural biodegradable polysaccharides having pendent coupling... |
|
US20070026073 |
Amorphous efavirenz and the production thereof
Efavirenz compositions of enhanced bioavailability are described that contain efavirenz with at least one solubility-enhancing polymer. Described methods to produce the bioenhanced products... |
|
US20050266087 |
Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
A suspension formulation for therapeutic use includes a non-aqueous, hydrophobic vehicle exhibiting viscous fluid characteristics, a dry particle formulation comprising a biomolecule dispersed in... |
|
US20050238723 |
Method of producing hydroxyalkyl starch derivatives
The present invention relates to methods of producing hydroxyalkyl starch (HAS) derivatives having a structure according to formula (I) comprising reacting HAS of formula (I) at its optionally... |
|
US20050220882 |
Materials for medical implants and occlusive devices
An embodiment is a swellable medical device that swells after introduction into a patient to occlude a lumen or void in a patient. The device may be anisotropically swellable so that it swells... |
|
US20050175706 |
Sustained release oral formulations
Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigmine, in a time-controlled manner. |
|
US20050053665 |
Nicotine formulations and use thereof
Nicotine-containing pharmaceutical compositions wherein nicotine is absorbed into and/or adsorbed onto cellulose of non-seed organism origin, especially cellulose from algae, bacteria and/or fungi. |
|
US20140242162 |
PHARMACEUTICAL COMPOSITIONS COMPRISING 40 - O - ( 2 - HYDROXY) ETHYL - RAPAMYCIN
The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical... |
|
US20120021053 |
CONTROLLED RELEASE AND TASTE-MASKING ORAL PHARMACEUTICAL COMPOSITION
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic,... |
|
US20110244032 |
DISPERSIBLE PHOSPHOLIPID STABILIZED MICROPARTICLES
Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of... |
|
US20090232891 |
Cell Transport Compositions and Uses Thereof
Compositions and methods have been developed for transporting compounds across membranes with little or no toxicity and, when targeted through the appropriate routes of administration (i.e., lung,... |
|
US20080020026 |
Hemostatic compositions and methods for controlling bleeding
The invention provides hemostatic compositions useful to promote hemostasis at active bleeding wound sites. The hemostatic compositions typically include an article containing cellulose, e.g.,... |
|
US20070259045 |
Alcohol Resistant Dosage Forms
Disclosed in certain embodiments is a controlled release dosage form comprising a matrix comprising a pharmaceutically acceptable salt of an opioid analgesic in a controlled release material;... |
|
US20070196489 |
TASTE MASKED PHARMACEUTICAL PARTICLES
Taste masked particles and chewable tablets made therefrom are disclosed. The taste masked particles comprise a core containing an active ingredient and a polymeric coating covering said core,... |
|
US20070053987 |
Cross-linked polysacharide and protein matrices and methods for their preparation
Methods for preparing cross-linked polysaccharide matrices by cross-linking one or more amino group containing polysaccharides or amino-functionalized polysaccharides with reducing sugars and/or... |
|
US20060078617 |
Pharmaceutical compositions for the treatment of cancer
This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of Formula I below, to processes for preparing these novel pharmaceutical compositions and... |
|
US20050266089 |
Contact lens and eye drop rewetter compositions and methods
Stable ophthalmic formulations comprising hyaluronic acid (sodium hyaluronate) as the primary active demulcent ingredient, stabilized oxy-chloro complex (available commercially as OcuPure™ from... |
|
US20050249799 |
Polymeric drug delivery system for hydrophobic drugs
An oral delivery system for Class II drugs that have low oral bioavailability due to their insolubility in water and slow dissolution kinetics and method for making such a drug delivery system are... |
|
US20050232872 |
Compositions and methods for enhancing receptor-mediated cellular internalization
Compositions and methods for improving cellular internalization of one or more compounds are disclosed. The compositions include a compound to be delivered and a biocompatible viscous material,... |
|
US20050191270 |
Anti-infectious hydrogel compositions
The present invention provides a hydrogel composition capable of preventing the intrusion of micro-organisms into body cavities or body openings of mammals comprising of a poly(N-vinyl lactam), a... |
|
US20050084516 |
PROCESS FOR MAKING GEL FILMS
Abstract of the Disclosure The present invention is directed to a process for making homogeneous, thermoreversible gel films comprising the steps of: (i) heating, hydrating, mixing, solubilizing,... |
|
US20140112980 |
ABUSE-RESISTANT PHARMACEUTICAL COMPOSITIONS
An abuse-resistant controlled release pharmaceutical composition comprising a pharmaceutically effective amount of discrete particles of an active capable of abuse, wherein surfaces of said... |
|
US20140086988 |
Stabilized Protein Crystals, Formulations Containing Them and Methods of Making Them
This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention... |
|
US20100233266 |
ARTICLES AND METHODS OF TREATING VASCULAR CONDITIONS
The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from... |
|
US20100166855 |
ORAL INSULIN COMPOSITION AND METHODS OF MAKING AND USING THEREOF
A method of lowering blood glucose in a mammal includes orally administering a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood... |
|
US20100151029 |
Anti-infectious hydrogel compositions
The present invention provides a hydrogel composition capable of preventing the intrusion of micro-organisms into body cavities or body openings of mammals comprising of a poly(N-vinyl lactam), a... |
|
US20080260836 |
Films Comprising a Plurality of Polymers
Films are disclosed that comprise a first polymer and a second polymer having a solubility temperature lower than that of the first polymer; wherein the breaking strength of the film is greater... |
|
US20080213370 |
Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the... |
|
US20070292479 |
Film-shaped drug forms for use in the oral cavity (wafers)
The present invention describes film-shaped systems capable of transmucosal buccal application and comprising at least one steroid hormone from the group of the androgens, the progestogens and the... |
|
US20070148248 |
Gastric reflux resistant dosage forms
Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent.... |
|
US20070122476 |
Storage stable thyroxine active drug formulations and methods for their production
This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an... |
|
US20060115533 |
Pharmaceutical compositions
A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium. |
|
US20050271728 |
High molecular weight medicine-containing preparation in powder form for administration through mucosa
A preparation in powder form for administration through mucosa, comprising a medicine of high molecular weight and a cationic polymer is disclosed. By adding a cationic polymer (in particular, a... |
|
US20050013856 |
Solid dispersions comprising a hygroscopic and/or deliquescent drug
A pharmaceutical composition is provided comprising a drug and a carrier medium, wherein the carrier medium comprisese (a) a matrix forming agent selected from the group consisting of... |
|
US20150118295 |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including... |
|
US20120231075 |
ABUSE-RESISTANT OPIOID DOSAGE FORM
We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix. |
|
US20120130300 |
Therapeutic Methods Using Controlled Delivery Devices Having Zero Order Kinetics
An injectable or implantable medical device having orifice(s) on the surface that release an active agent with zero-order release kinetics is described herein. The device is a hollow matrix of any... |